S. Schwab

Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.

O. Burghuber, H. Prosch, M. Hochmair, 2017, Lung cancer.

Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient

H. Prosch, M. Hochmair, S. Schwab, 2017, Anti-cancer drugs.

Cell‐Free Plasma DNA‐Guided Treatment With Osimertinib in Patients With Advanced EGFR‐Mutated NSCLC

Peter Schenk, Helmut Prosch, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.

A. Valipour, O. Burghuber, M. Hochmair, 2019, Anti-cancer drugs.

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.

W. Wadsak, C. Herold, A. Haug, 2019, Clinical nuclear medicine.

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

O. Burghuber, M. Filipits, H. Prosch, 2018, Targeted Oncology.

P2.03-025 Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib

O. Burghuber, M. Filipits, M. Hochmair, 2017 .

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR

O. Burghuber, R. Pirker, M. Filipits, 2019, Targeted Oncology.